Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 6-month & 18-month Prospective, Randomized, Placebo-controlled, Double-blind Dual Clinical Trial Investigating Efficacy and Safety of Buntanetap in Treating Participants of Early Alzheimer's Disease

Next Previous
Trial Profile

A 6-month & 18-month Prospective, Randomized, Placebo-controlled, Double-blind Dual Clinical Trial Investigating Efficacy and Safety of Buntanetap in Treating Participants of Early Alzheimer's Disease

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Buntanetap (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Annovis Bio

Most Recent Events

  • 12 Aug 2025 According to an Annovis Bio media release, 76 U.S. sites secured and 46 currently enrolling patients. The remaining sites are expected to begin enrollment shortly. This pivotal Phase 3 trial has attracted strong participation, with 38 patients already receiving buntanetap or placebo and nearly 200 more in screening a number that continues to grow each day with screen failure rate being as expected at 50%.
  • 26 Jun 2025 According to an Annovis Bio media release, the company will present a poster highlighting the data of the study at Alzheimer's Association International Conference (AAIC), taking place July 27-31, 2025, in Toronto, Canada.
  • 21 Mar 2025 According to an Annovis Bio media release, The symptomatic data is anticipated in mid-2026, followed by the disease-modifying data in mid-2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top